SRC and colorectal carcinoma: Among the compounds, 2 MEK inhibitors (Trametinib and TAK- 733), 2 VEGFR inhibitors (Apatinib and Nintedanib), a BTK inhibitor (AVL-290) and an SRC inhibitor (PP1) showed the greater selectivity toward PTEN+/+ CRC cells.